Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1

HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.

Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates

Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.

National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls

National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.

Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline

Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.

Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y

Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.

Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates

Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.

LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1

LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.

Sweta Jaiswal, FRM headshot

Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions.

Globus Medical (GMED) Misses on Q1 Earnings and Revenues

Globus Medical (GMED) witnesses around $20 million of COVID-19 related adverse impact on its Q1 sales.

Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises

Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.

Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top

Avanos Medical's (AVNS) first-quarter results benefit from segmental contribution.

DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results

DENTSPLY SIRONA's (XRAY) first-quarter 2020 preliminary results reflect weak segmental performance and decline in revenues.

Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook

Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended

Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls

Amedisys (AMED) notes that COVID-19 started impacting its volumes and costs beginning the second half of March.

NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up

QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.

AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.